Jovana Prodanovic Simeunovic

Jovana Prodanovic Simeunovic

Auto-generated profile, based on publicly available information

Jovana Prodanovic Simeunovic

University of Novi Sad Faculty of Medicine Novi Sad Serbia University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2023 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
DNDragana Tomic Tomic Naglic
Dragana Tomic Tomic Naglic
MMMia Manojlović
Mia Manojlović
SPSlađana Pejaković
Slađana Pejaković
KSKristina Stepanovic
Kristina Stepanovic
JSJovana Prodanovic Simeunovic
Jovana Prodanovic Simeunovic
Atherosclerosis is a chronic process characterized by inflammation and the progressive accumulation of inflammatory cells and lipids in the blood vessel wall, resulting in narrowing of the blood vessel’s circumference. Treatment of people with dyslipidemia aims to reduce the risk of developing atherosclerotic disease and prevent major adverse cardiovascular events (MACE). The results of previous studies indicated that lipoprotein(a) (Lp(a)) is a critical causal factor in the estimated risk of developing a cardiovascular (CV) incident even after achieving desirable low-density lipoprotein (LDL) cholesterol levels. Lp(a) is a low-density lipoprotein particle, like LDL cholesterol. The levels of Lp(a) in plasma are genetically determined. Lp(a) catabolism is still controversial. The pathogenic potential of Lp(a) can be divided into three categories: promotion of plaque formation, thrombogenicity, and proinflammatory effects. Lp(a) levels above the 75th percentile reduced the risk of aortic valve stenosis and myocardial infarction, whereas higher levels (above 90th percentile) were associated with an increased risk of heart failure. However, no hypolipidemic agents have been approved for targeted use in patients with high Lp(a) levels. There are insufficient randomized controlled trials assessing CV outcomes that would support the evidence that current treatment options, which effectively lower Lp(a) levels, also effectively prevent CV event. However, according to some studies, there is strong evidence that better CV outcome is one of the benefits of such therapy. The results of ongoing clinical trials are eagerly awaited.

29 April 2024 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
TITijana Ičin
Tijana Ičin
KSKristina Stepanovic
Kristina Stepanovic
IBIvana Bajkin
Ivana Bajkin
NBNikola Boban
Nikola Boban
DADragan Anđelić
Dragan Anđelić
ZSZeljka Savic
Zeljka Savic
SUMMARY Hypopituitarism is a rare clinical condition that can present as a partial or complete absence of pituitary hormones. Hypopituitarism is most commonly caused by a sellar or parasellar mass, particularly a tumor, and the gold standard for its differential diagnosis is magnetic resonance imaging (MRI). Intrasellar aneurysm is an unusual cause of hypopituitarism. Indeed, about 0.17% of all cases of hypopituitarism are due to intrasellar aneurysms. We report the case of a 72-year-old man who was admitted to the [...] SUMMARY Hypopituitarism is a rare clinical condition that can present as a partial or complete absence of pituitary hormones. Hypopituitarism is most commonly caused by a sellar or parasellar mass, particularly a tumor, and the gold standard for its differential diagnosis is magnetic resonance imaging (MRI). Intrasellar aneurysm is an unusual cause of hypopituitarism. Indeed, about 0.17% of all cases of hypopituitarism are due to intrasellar aneurysms. We report the case of a 72-year-old man who was admitted to the